R. Ávila

MicroRNAs (miRNAs) as predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer (RCC).

C. Rodríguez-Antona, J. García-Donas, I. Durán, 2017 .

The role of microRNAs (miRNAs) as predictive biomarker in advanced renal cell carcinoma (mRCC) patients (pts) with “extreme response” to tyrosine kinase inhibitors (TKIs) treatment.

C. Rodríguez-Antona, J. García-Donas, I. Durán, 2017 .

Cutaneous Hodgkin‐type lymphoproliferative lesion associated with immunomodulatory therapy for ulcerative colitis

M. Biscuola, R. Ávila, B. Vieites, 2011, Journal of cutaneous pathology.

A Roma founder BIN1 mutation causes a novel phenotype of centronuclear myopathy with rigid spine

D. Comas, N. Romero, N. Laing, 2018, Neurology.

Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction

M. Ruíz-Borrego, R. Ávila, C. Castilla, 2012, Breast Cancer Research and Treatment.

Unusual co-occurrence of Hodgkin lymphoma and hemophagocytic lymphohistiocytosis in a bone marrow aspirate

R. Ávila, J. Borrero, M. T. Vargas, 2016, Annals of Hematology.